SARS-CoV-2 infection in patients with autoimmune hepatitis.
COVID-19
SARS-CoV-2
autoimmune hepatitis
coronavirus
immunosuppression
liver disease
Journal
Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
01
12
2020
revised:
24
12
2020
accepted:
12
01
2021
pubmed:
29
1
2021
medline:
26
5
2021
entrez:
28
1
2021
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19) continues to have a devastating impact across the globe. However, little is known about the disease course in patients with autoimmune hepatitis (AIH). Data for patients with AIH and SARS-CoV-2 infection were combined from 3 international reporting registries and outcomes were compared to those in patients with chronic liver disease of other aetiology (non-AIH CLD) and to patients without liver disease (non-CLD). Between 25 Patients with AIH were not at increased risk of adverse outcomes despite immunosuppressive treatment compared to other causes of CLD and to matched cases without liver disease. Little is known about the outcomes of COVID-19 in patients with autoimmune hepatitis (AIH), a rare chronic inflammatory liver disease. This study combines data from 3 large registries to describe the course of COVID-19 in this patient group. We show that AIH patients do not appear to have an increased risk of death from COVID-19 compared to patients with other forms of liver disease and compared to patients without liver disease, despite the use of medications which suppress the immune system.
Sections du résumé
BACKGROUND & AIMS
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19) continues to have a devastating impact across the globe. However, little is known about the disease course in patients with autoimmune hepatitis (AIH).
METHODS
Data for patients with AIH and SARS-CoV-2 infection were combined from 3 international reporting registries and outcomes were compared to those in patients with chronic liver disease of other aetiology (non-AIH CLD) and to patients without liver disease (non-CLD).
RESULTS
Between 25
CONCLUSION
Patients with AIH were not at increased risk of adverse outcomes despite immunosuppressive treatment compared to other causes of CLD and to matched cases without liver disease.
LAY SUMMARY
Little is known about the outcomes of COVID-19 in patients with autoimmune hepatitis (AIH), a rare chronic inflammatory liver disease. This study combines data from 3 large registries to describe the course of COVID-19 in this patient group. We show that AIH patients do not appear to have an increased risk of death from COVID-19 compared to patients with other forms of liver disease and compared to patients without liver disease, despite the use of medications which suppress the immune system.
Identifiants
pubmed: 33508378
pii: S0168-8278(21)00033-7
doi: 10.1016/j.jhep.2021.01.021
pmc: PMC7835076
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1335-1343Subventions
Organisme : NIDDK NIH HHS
ID : T32 DK007634
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002489
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002489
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest The authors do not have any conflicts of interest. Please refer to the accompanying ICMJE disclosure forms for further details.
Références
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Gut. 2021 Apr;70(4):725-732
pubmed: 33082265
BMJ. 2017 May 23;357:j2099
pubmed: 28536104
Hepatology. 2020 Jul;72(1):287-304
pubmed: 32298473
Clin Gastroenterol Hepatol. 2020 Sep;18(10):2369-2371.e1
pubmed: 32480009
Am J Transplant. 2020 Nov;20(11):3008-3018
pubmed: 32780493
Lancet Gastroenterol Hepatol. 2020 Nov;5(11):1008-1016
pubmed: 32866433
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Hepatol Commun. 2020 Jun 09;:
pubmed: 32838102
Clin Gastroenterol Hepatol. 2020 Sep 17;:
pubmed: 32950749
J Hepatol. 2020 Sep;73(3):702-705
pubmed: 32413378
Ann Rheum Dis. 2020 Jul;79(7):859-866
pubmed: 32471903
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
JHEP Rep. 2020 Oct;2(5):100169
pubmed: 32835190
Scand J Gastroenterol. 2008;43(10):1232-40
pubmed: 18609163
J Hepatol. 2021 Jan;74(1):148-155
pubmed: 32750442
J Hepatol. 2020 Nov;73(5):1063-1071
pubmed: 32526252
J Hepatol. 2021 Mar;74(3):567-577
pubmed: 33035628
Health Serv Res. 2014 Oct;49(5):1701-20
pubmed: 24779867
J Hepatol. 2014 Mar;60(3):612-7
pubmed: 24326217
Gut. 2021 Mar;70(3):531-536
pubmed: 32660964